Related references
Note: Only part of the references are listed.Safety and efficacy of anti-PD-1 antibody dostarlimab in patients (pts) with mismatch repair-deficient (dMMR) solid cancers: Results from GARNET study.
Thierry Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design
Ajay K. Nooka et al.
FUTURE ONCOLOGY (2021)
ENGOT-OV44/FIRST study: a randomized, double-blind, adaptive, phase III study of standard of care (SOC) platinum-based therapy ± dostarlimab followed by niraparib ± dostarlimab maintenance as first-line (1L) treatment of stage 3 or 4 ovarian cancer (OC).
Anne-Claire Hardy-Bessard et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ENGOT-EN6/NSGO-RUBY: A phase III, randomized, double-blind, multicenter study of dostarlimab + carboplatin-paclitaxel versus placebo + carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer (EC).
Mansoor Raza Mirza et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Randomized, open-label, phase II trial of dostarlimab (TSR-042), as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation: ATOMICC study
A. Oaknin et al.
ANNALS OF ONCOLOGY (2020)
JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC)
S. S. Ramalingam et al.
ANNALS OF ONCOLOGY (2020)
Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
J. Subramanian et al.
ANNALS OF ONCOLOGY (2020)
MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib plus dostarlimab in patients with platinum-resistant ovarian cancer
L. M. Randall et al.
ANNALS OF ONCOLOGY (2020)
Clinical Activity and Safety of the Anti-Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair-Deficient Endometrial Cancer A Nonrandomized Phase 1 Clinical Trial
Ana Oaknin et al.
JAMA ONCOLOGY (2020)
SAFETY AND ANTITUMOR ACTIVITY OF DOSTARLIMAB IN PATIENTS (PTS) WITH ADVANCED OR RECURRENT DNA MISMATCH REPAIR DEFICIENT (DMMR) OR PROFICIENT (MMRP) ENDOMETRIAL CANCER (EC): RESULTS FROM THE GARNET STUDY
Ana Oaknin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)
IOLite: Multipart, phase 1b, dose-finding study of the PD-1 inhibitor dostarlimab in combination with the PARP inhibitor niraparib ± bevacizumab (bev), or with platinum-based chemotherapy ± bev for advanced cancer.
Nashat Y. Gabrail et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Identification and characterization of TSR-042, a novel anti-human PD-1 therapeutic antibody
H. Laken et al.
EUROPEAN JOURNAL OF CANCER (2016)
Share Paper
